Table 2.
Participant characteristics in the replication cohorts
| Sub-group | Children replication cohort | Adult replication cohort | |
|---|---|---|---|
| General population (n = 407) | Obesity clinic (n = 590) | GALA–ALD/HP (n = 558) | |
| Age, mean (s.d.), years | 12 (3) | 12 (3) | 56 (10) |
| Female sex, no. (%) | 259 (64) | 320 (54) | 148 (73) |
| Male sex, no. (%) | 148 (36) | 270 (46) | 410 (27) |
| BMI, mean (s.d.), kg m−2 | 17.7 (2.3) | 26.9 (5.4) | 27.2 (5) |
| BMI-SDS, mean (s.d.) | −0.08 (0.8) | 2.76 (0.75) | NA |
| Tanner stage 1/2–5, no. (%) | 83/214 (28/72) | 149/259 (37/63) | NA |
| ALT, U l−1 | 20 (17–23) | 22 (18–30) | 28 (21–42) |
| AST, U l−1 | 25 (21–32) | 26 (21.7–31) | 30 (24–46) |
| GGT, U l−1 | 16 (13–19) | 16 (13–20) | 48 (25–136) |
| Glucose, mmol l−1 | 5 (4.7–5.2) | 5.1 (4.8–5.4) | 6 (5.5–6.6) |
| Insulin, pmol l−1 | 52.9 (35.4–69.3) | 78.5 (53.8–124.1) | NA |
| HbA1c, mmol mol−1 | 34 (31–35) | 34 (32–36) | 36 (33–39) |
| Triglycerides, mmol l−1 | 0.6 (0.5–0.8) | 0.9 (0.6–1.4) | 1.2 (0.9–1.8) |
| Total cholesterol, mmol l−1 | 3.9 (3.4–4.3) | 4.2 (3.7–4.7) | 5 (4.4–5.9) |
| LDL cholesterol, mmol l−1 | 2 (1.7–2.4) | 2.4 (2–2.9) | 3 (2.3–3.6) |
| HDL cholesterol, mmol l−1 | 1.5 (1.3–1.7) | 1.2 (1–1.4) | 1.3 (1.1–1.7) |
| Abstaining from alcohol at time of inclusion, no. (%) | NA | NA | 197 (35) |
| Statin use prior time of inclusion, no. (%) | NA | NA | 97 (17) |
| Steatosis 0/1/2/3, no. | NA | NA | 373/79/70/36 |
| Inflammatory activity 0/1/2/3/4/5, no. | NA | NA | 290/90/78/50/28/22 |
| Fibrosis stage 0–1/2/3/4, no. | NA | NA | 367/102/26/63 |
GALA–ALD/HP, gut and liver axis–alcohol-related liver disease/healthy participants. Data are shown as median (interquartile range) unless otherwise noted.